[1] Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B.Neuromyelitis optica[J].Nat Rev Dis Primers, 2020, 6:85.
[2] Tian DC, Li Z, Yuan M, Zhang C, Gu H, Wang Y, Shi FD.Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China:a national population-based study[J].Lancet Reg Health West Pac, 2020, 2:100021.
[3] Current status of rare disease NMOSD patients in China:Asian population is more susceptible to the diseaese and it takes an verage of four years to be diagnosed[EB/OL].(2020-05-25)[2022-09-19].https://finance.sina.com.cn/chanjing/cyxw/2020-05-25/doc-iircuyvi4872752.shtml.[中国罕见病NMOSD患者现状:亚洲人群更易感平均四年才能确诊[EB/OL] (.2020-05-25)[2022-09-19].https://finance.sina.com.cn/chanjing/cyxw/2020-05-25/doc-iircuyvi4872752.shtml.]
[4] Nathan FM, Ohtake Y, Wang S, Jiang X, Sami A, Guo H, Zhou FQ, Li S.Upregulating Lin28a promotes axon regeneration in adult mice with optic nerve and spinal cord injury[J].Mol Ther, 2020, 28:1902-1917.
[5] Varadarajan SG, Hunyara JL, Hamilton NR, Kolodkin AL, Huberman AD.Central nervous system regeneration[J].Cell, 2022, 185:77-94.
[6] Horgusluoglu E, Nudelman K, Nho K, Saykin AJ.Adult neurogenesis and neurodegenerative diseases:a systems biology perspective[J].Am J Med Genet B Neuropsychiatr Genet, 2017, 174:93-112.
[7] Elbaz B, Popko B.Molecular control of oligodendrocyte development[J].Trends Neurosci, 2019, 42:263-277.
[8] Kremer D, Göttle P, Hartung HP, Küry P.Pushing forward:remyelination as the new frontier in CNS diseases[J].Trends Neurosci, 2016, 39:246-263.
[9] Liu Y, Given KS, Owens GP, Macklin WB, Bennett JL.Distinct patterns of glia repair and remyelination in antibody-mediated demyelination models of multiple sclerosis and neuromyelitis optica[J].Glia, 2018, 66:2575-2588.
[10] Lubetzki C, Zalc B, Williams A, Stadelmann C, Stankoff B.Remyelination in multiple sclerosis:from basic science to clinical translation[J].Lancet Neurol, 2020, 19:678-688.
[11] Villoslada P, Steinman L.New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis[J].Expert Opin Investig Drugs, 2020, 29:443-459.
[12] Pan S, Chan JR.Clinical applications of myelin plasticity for remyelinating therapies in multiple sclerosis[J].Ann Neurol, 2021, 90:558-567.
[13] Wrzos C, Winkler A, Metz I, Kayser DM, Thal DR, Wegner C, Brück W, Nessler S, Bennett JL, Stadelmann C.Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions[J].Acta Neuropathol, 2014, 127:523-538.
[14] Lloyd AF, Miron VE.Cellular and molecular mechanisms underpinning macrophage activation during remyelination[J].Front Cell Dev Biol, 2016, 4:60.
[15] Kuhn S, Gritti L, Crooks D, Dombrowski Y.Oligodendrocytes in development, myelin generation and beyond[J].Cells, 2019, 8:1424.
[16] Blakemore WF, Gilson JM, Crang AJ.The presence of astrocytes in areas of demyelination influences remyelination
[17] Liu Y, Given KS, Harlow DE, Matschulat AM, Macklin WB, Bennett JL, Owens GP.Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination[J].Acta Neuropathol Commun, 2017, 5:25.
[18] Tsai HH, Niu J, Munji R, Davalos D, Chang J, Zhang H, Tien AC, Kuo CJ, Chan JR, Daneman R, Fancy SP.Oligodendrocyte precursors migrate along vasculature in the developing nervous system[J].Science, 2016, 351:379-384.
[19] Weber MS, Derfuss T, Metz I, Brück W.Defining distinct features of anti-MOG antibody associated central nervous system demyelination[J].Ther Adv Neurol Disord, 2018, 11:1756286418762083.
[20] Yao X, Su T, Verkman AS.Clobetasol promotes remyelination in a mouse model of neuromyelitis optica[J].Acta Neuropathol Commun, 2016, 4:42.
[21] Tradtrantip L, Asavapanumas N, Verkman AS.Emerging therapeutic targets for neuromyelitis optica spectrum disorder[J].Expert Opin Ther Targets, 2020, 24:219-229.
[22] Luo W, Xu H, Xu L, Jiang W, Chen C, Chang Y, Liu C, Tian Z, Qiu X, Xie C, Li X, Chen H, Lai S, Wu L, Cui Y, Tang C, Qiu W.Remyelination in neuromyelitis optica spectrum disorder is promoted by edaravone through mTORC1 signaling activation[J].Glia, 2022.[Epub ahead of print]
[23] Rodney C, Rodney S, Millis RM.Vitamin D and demyelinating diseases:neuromyelitis optica (NMO) and multiple sclerosis (MS)[J].Autoimmune Dis, 2020:ID8718736.
[24] Derdelinckx J, Reynders T, Wens I, Cools N, Willekens B.Cells to the rescue:emerging cell-based treatment approaches for NMOSD and MOGAD[J].Int J Mol Sci, 2021, 22:7925.
[25] Hoay KY, Ratnagopal P.Autologous hematopoietic stem cell transplantation for the treatment of neuromyelitis optica in Singapore[J].Acta Neurol Taiwan, 2018, 27:26-32.J, Jovanovic
[26] Burt RK, Balabanov R, Han X, Burns C, Gastala B, Helenowski I, Jitprapaikulsan J, Fryer JP, Pittock SJ.Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica[J].Neurology, 2019, 93:e1732-1741.
[27] Lu Z, Zhu L, Liu Z, Wu J, Xu Y, Zhang CJ.IV/IT hUC-MSCs infusion in RRMS and NMO:a 10-year follow-up study[J].Front Neurol, 2020, 11:967.
[28] Fu Y, Yan Y, Qi Y, Yang L, Li T, Zhang N, Yu C, Su L, Zhang R, Shen Y, Lin S, Liu Q, Shao Z, Han Z, Shi FD.Impact of autologous mesenchymal stem cell infusion on neuromyelitis optica spectrum disorder:a pilot, 2-year observational study[J].CNS Neurosci Ther, 2016, 22:677-685.
[29] Anderson MA, O'Shea TM, Burda JE, Ao Y, Barlatey SL, Bernstein AM, Kim JH, James ND, Rogers A, Kato B, Wollenberg AL, Kawaguchi R, Coppola G, Wang C, Deming TJ, He Z, Courtine G, Sofroniew MV.Required growth facilitators propel axon regeneration across complete spinal cord injury[J].Nature, 2018, 561:396-400.
[30] Herwerth M, Kenet S, Schifferer M, Winkler A, Weber M, Snaidero N, Wang M, Lohrberg M, Bennett JL, Stadelmann C, Hemmer B, Misgeld T.A new form of axonal pathology in a spinal model of neuromyelitis optica[J].Brain, 2022, 145:1726-1742.multiple
[31] Kawachi I, Lassmann H.Neurodegeneration in sclerosis and neuromyelitis optica[J].J Neurol Neurosurg Psychiatry, 2017, 88:137-145.
[32] Schattling B, Steinbach K, Thies E, Kruse M, Menigoz A, Ufer F, Flockerzi V, Brück W, Pongs O, Vennekens R, Kneussel M, Freichel M, Merkler D, Friese MA.TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis[J].Nat Med, 2012, 18:1805-1811.
[33] Giaume C, Leybaert L, Naus CC, Sáez JC.Connexin and pannexin hemichannels in brain glial cells:properties, pharmacology, and roles[J].Front Pharmacol, 2013, 4:88.
[34] Masaki K, Suzuki SO, Matsushita T, Matsuoka T, Imamura S, Yamasaki R, Suzuki M, Suenaga T, Iwaki T, Kira J.Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica[J].PLoS One, 2013, 8:e72919.
[35] May D, Tress O, Seifert G, Willecke K.Connexin 47 protein phosphorylation and stability in oligodendrocytes depend on expression of connexin 43 protein in astrocytes[J].J Neurosci, 2013, 33:7985-7996.
[36] Orellana JA, Froger N, Ezan P, Jiang JX, Bennett MV, Naus CC, Giaume C, Sáez JC.ATP and glutamate released via astroglial connexin 43 hemichannels mediate neuronal death through activation of pannexin 1 hemichannels[J].J Neurochem, 2011, 118:826-840.S, Ransom BR.Functional
[37] Ye ZC, Wyeth MS, Baltan-Tekkok hemichannels in astrocytes:a novel mechanism of glutamate release[J].J Neurosci, 2003, 23:3588-3596.
[38] Richard C, Ruiz A, Cavagna S, Bigotte M, Vukusic S, Masaki K, Suenaga T, Kira JI, Giraudon P, Marignier R.Connexins in neuromyelitis optica:a link between astrocytopathy and demyelination[J].Brain, 2020, 143:2721-2732. |